Wed 7/18/2018 19:57 ET
DJIA25199.2979.400.32%TELCO159.460.620.39%GOLD1227.200.740.06%Shanghai2787.2610.870.39%
S&P 5002815.626.190.22%BANKS475.753.470.73%OIL67.860.110.16%BITCOIN7368.0641.260.56%
NASDAQ7854.440.790.01%PHARM523.820.840.16%US/EU1.170.000.26%Futures2811.3014.800.53%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Pinks and BB (ICO THERAPEUTICS - ICOTF)    Pinks And BB Top Stock Picks

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ICOTF
  
From: stormcat (Rep: 440)Date: 07/10/2018 14:30
Forum: Pinks and BB - Msg #127749 - List ICOTF msgs Thread #674020318 (Rec: 0)
iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
Newsfile
Newsfile Corp.
,Newsfile•June 27, 2018
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse events (SAEs) and no drug-related adverse events (AEs) in either of the four study cohorts. All drug doses were well tolerated, including the highest dose of 800 mg, with no indication of kidney toxicity. "This is a very promising result for our future efficacy studies with oral Amphotericin B" stated Dr. Peter Hnik, CMO of iCo Therapeutics.

"We are pleased to report a positive primary endpoint related to our 32 subject Phase 1 clinical study" stated Andrew Rae, President and CEO of iCo Therapeutics Inc. "No patients experienced drug-related adverse or serious adverse events in our Phase 1 clinical study and we believe this allows us to claim leadership in the race towards developing an oral Amphotericin B drug." Mr. Rae also stated, "iCo Management waits with anticipation important and material pharmacokinetic data in the coming weeks."

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser stormcat: Reward | Watch | IgnoreICOTF: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ICOTF
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.